Advertisement

Tumor Biology

, Volume 32, Issue 5, pp 1013–1021 | Cite as

Plasma membrane proteomic analysis of human osteosarcoma and osteoblastic cells: revealing NDRG1 as a marker for osteosarcoma

  • Yingqi Hua
  • Xiaofang Jia
  • Mengxiong Sun
  • Longpo Zheng
  • Lin Yin
  • Lijun Zhang
  • Zhengdong Cai
Research Article

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. To identify new biomarkers for early diagnosis of OS and novel therapeutic candidates, we carried out a plasma membrane proteomic study based on two-dimensional electrophoresis (2DE). The OS cell line MG-63 and the human osteoblastic cell line hFOB1.19 were adopted as the comparison model. We extracted plasma membrane by aqueous two-phase partition extraction. The proteins were separated through 2DE. We analyzed the differentially expressed proteins by Imagemaster software and then identified them by liquid chromatography–tandem mass spectrometry, and the location and function of differential proteins were searched through the Gene Ontology database. In total, 220 protein spots were separated by 2DE. Seven proteins with more than 2.0-folds of difference were successfully identified from 13 gel spots, with 6 up-regulated and 1 down-regulated. Gene Ontology analysis of the differentially expressed proteins indicated that these proteins were involved in seven kinds of functions including binding, structural, cell motility, receptor activity, electron carrier activity, NADH dehydrogenase (ubiquinone) activity, and transcription repressor activity. The up-regulation of NDRG1 was verified in osteosarcoma through Western blotting and by immunohistochemistry in paraffin-embedded tissues. The plasma membrane proteins identified in this study may provide new insights into osteosarcoma cancer biology and potential diagnostic and therapeutic biomarkers.

Keywords

Osteosarcoma Plasma membrane Proteomics NDRG1 2DE 

Abbreviations

OS

Osteosarcoma

2DE

Two-dimensional electrophoresis

LC–MS

Liquid chromatography–mass spectrometry

MS/MS

Tandem MS

HCT

High capacity trap

HE

Hematoxylin and eosin

Notes

Acknowledgments

We thank the grants from the National 973 Project of China (2011CB910700), Shanghai Natural Science Foundation (09ZR1426300), and Shanghai Hospital Clinical Research Platform for Clinical Research Source (No. SHDC12007203). We thank Kirill Gorshkov for carefully editing the whole manuscript.

Conflicts of interest

None

Supplementary material

13277_2011_203_Fig6_ESM.jpg (16 kb)
Figure S1

The SDS-PAGE gels of 50 ug MG and Normal PM proteins to make sure equal protein load for western blotting analysis. (JPEG 15 kb)

13277_2011_203_MOESM1_ESM.tif (888 kb)
High resolution image (TIFF 887 kb)
13277_2011_203_MOESM2_ESM.xls (24 kb)
Table S1 Table S1 Lists of non-redundant peptides identified in each protein spot. (XLS 24 kb)
13277_2011_203_MOESM3_ESM.xls (113 kb)
Table S2 Information of proteins involved in protein-protein interaction network. (XLS 113 kb)

References

  1. 1.
    Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res. 2004;(429):286–91.Google Scholar
  2. 2.
    Leth-Larsen R, Lund RR, Ditzel HJ. Plasma membrane proteomics and its application in clinical cancer biomarker discovery. Mol Cell Proteomics. 2010;9:1369–82.PubMedCrossRefGoogle Scholar
  3. 3.
    Sprenger RR, Jensen ON. Proteomics and the dynamic plasma membrane: quo vadis? Proteomics. 2010;10:3997–4011.PubMedCrossRefGoogle Scholar
  4. 4.
    Bhattacharyya S, Byrum S, Siegel ER, Suva LJ. Proteomic analysis of bone cancer: a review of current and future developments. Expert Rev Proteomics. 2007;4:371–8.PubMedCrossRefGoogle Scholar
  5. 5.
    Byrum S, Montgomery CO, Nicholas RW, Suva LJ. The promise of bone cancer proteomics. Ann N Y Acad Sci. 2010;1192:222–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Folio C, Mora MI, Zalacain M, Corrales FJ, Segura V, Sierrasesumaga L, et al. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. J Proteome Res. 2009;8:3882–8.PubMedCrossRefGoogle Scholar
  7. 7.
    Guo QC, Shen JN, Jin S, Wang J, Huang G, Zhang LJ, et al. Comparative proteomic analysis of human osteosarcoma and sv40-immortalized normal osteoblastic cell lines. Acta Pharmacol Sin. 2007;28:850–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Zhang Z, Zhang L, Hua Y, Jia X, Li J, Hu S, et al. Comparative proteomic analysis of plasma membrane proteins between human osteosarcoma and normal osteoblastic cell lines. BMC Cancer. 2010;10:206.PubMedCrossRefGoogle Scholar
  9. 9.
    Cao R, Li X, Liu Z, Peng X, Hu W, Wang X, et al. Integration of a two-phase partition method into proteomics research on rat liver plasma membrane proteins. J Proteome Res. 2006;5:634–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Zhang L, Jia X, Zhang X, Sun J, Peng X, Qi T, et al. Proteomic analysis of PBMCs: characterization of potential HIV-associated proteins. Proteome Sci. 2010;8:12.PubMedCrossRefGoogle Scholar
  11. 11.
    Zhang L, Jia X, Zhang X, Cao J, Yang P, Qiu C, et al. Alpha-1 antitrypsin variants in plasma from HIV-infected patients revealed by proteomic and glycoproteomic analysis. Electrophoresis. 2010;31:3437–45.PubMedCrossRefGoogle Scholar
  12. 12.
    Zhang L, Xie J, Wang X, Liu X, Tang X, Cao R, et al. Proteomic analysis of mouse liver plasma membrane: use of differential extraction to enrich hydrophobic membrane proteins. Proteomics. 2005;5:4510–24.PubMedCrossRefGoogle Scholar
  13. 13.
    de Alava E. Molecular pathology in sarcomas. Clin Transl Oncol. 2007;9:130–44.PubMedCrossRefGoogle Scholar
  14. 14.
    Dass CR, Ek ET, Choong PF. PEDF as an emerging therapeutic candidate for osteosarcoma. Curr Cancer Drug Targets. 2008;8:683–90.PubMedCrossRefGoogle Scholar
  15. 15.
    Nikitovic D, Berdiaki K, Chalkiadaki G, Karamanos N, Tzanakakis G. The role of SLRP-proteoglycans in osteosarcoma pathogenesis. Connect Tissue Res. 2008;49:235–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Zhang L, Peng X, Zhang Z, Feng Y, Jia X, Shi Y, et al. Subcellular proteome analysis unraveled annexin A2 related to immune liver fibrosis. J Cell Biochem. 2010;110:219–28.PubMedGoogle Scholar
  17. 17.
    Zhang L, Jia X, Feng Y, Peng X, Zhang Z, Zhou W, et al. Plasma membrane proteome analysis of the early effect of alcohol on liver: implications for alcoholic liver disease. Acta Biochim Biophys Sin (Shanghai). 2011;43:19–29.CrossRefGoogle Scholar
  18. 18.
    Lubke T, Lobel P, Sleat DE. Proteomics of the lysosome. Biochim Biophys Acta. 2009;1793:625–35.PubMedCrossRefGoogle Scholar
  19. 19.
    Jung EU, Yoon JH, Lee YJ, Lee JH, Kim BH, Yu SJ, et al. Hypoxia and retinoic acid-inducible NDRG1 expression is responsible for doxorubicin and retinoic acid resistance in hepatocellular carcinoma cells. Cancer Lett. 2010;298:9–15.PubMedCrossRefGoogle Scholar
  20. 20.
    Sibold S, Roh V, Keogh A, Studer P, Tiffon C, Angst E, et al. Hypoxia increases cytoplasmic expression of NDRG1, but is insufficient for its membrane localization in human hepatocellular carcinoma. FEBS Lett. 2007;581:989–94.PubMedCrossRefGoogle Scholar
  21. 21.
    Angst E, Sibold S, Tiffon C, Weimann R, Gloor B, Candinas D, et al. Cellular differentiation determines the expression of the hypoxia-inducible protein NDRG1 in pancreatic cancer. Br J Cancer. 2006;95:307–13.PubMedCrossRefGoogle Scholar
  22. 22.
    Cangul H. Hypoxia upregulates the expression of the NDRG1 gene leading to its overexpression in various human cancers. BMC Genet. 2004;5:27.PubMedCrossRefGoogle Scholar
  23. 23.
    Gerhard R, Nonogaki S, Fregnani JH, Soares FA, Nagai MA. Ndrg1 protein overexpression in malignant thyroid neoplasms. Clinics (Sao Paulo). 2010;65:757–62.Google Scholar
  24. 24.
    Matsugaki T, Zenmyo M, Hiraoka K, Fukushima N, Shoda T, Komiya S, et al. N-myc downstream-regulated gene 1/Cap43 expression promotes cell differentiation of human osteosarcoma cells. Oncol Rep. 2010;24:721–5.PubMedGoogle Scholar
  25. 25.
    Wu M, Bai X, Xu G, Wei J, Zhu T, Zhang Y, et al. Proteome analysis of human androgen-independent prostate cancer cell lines: variable metastatic potentials correlated with vimentin expression. Proteomics. 2007;7:1973–83.PubMedCrossRefGoogle Scholar
  26. 26.
    Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, et al. Proteomic profiling for cancer progression: differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics. 2005;5:1024–32.PubMedCrossRefGoogle Scholar
  27. 27.
    He X, Cao X. Identification of alternatively spliced GRIM-19 mRNA in kidney cancer tissues. J Hum Genet. 2010;55:507–11.PubMedCrossRefGoogle Scholar
  28. 28.
    Li Y, Liang Q, Wen YQ, Chen LL, Wang LT, Liu YL, et al. Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet. 2010;198:97–106.PubMedCrossRefGoogle Scholar
  29. 29.
    Shimizu T, Chiqira M, Nagase M, Watanabe H, Udagawa E. HLA phenotypes in patients who have osteosarcoma. J Bone Jt Surg Am. 1990;72:68–70.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2011

Authors and Affiliations

  1. 1.Musculoskeletal Oncology Center, Shanghai 10th People’s HospitalTongji University School of MedicineShanghaiChina
  2. 2.Shanghai Public Health Clinical Center affiliated to Fudan UniversityShanghaiChina

Personalised recommendations